Review
Interindividual Variability in Nicotine Metabolism: C-Oxidation and Glucuronidation

https://doi.org/10.2133/dmpk.20.227Get rights and content

Summary:

Nicotine has roles in the addiction to smoking, replacement therapy for smoking cessation, as a potential medication for several diseases such as Parkinson's disease, Alzheimer's disease, and ulcerative colitis. The absorbed nicotine is rapidly and extensively metabolized and eliminated to urine. A major pathway of nicotine metabolism is C-oxidation to cotinine, which is catalyzed by CYP2A6 in human livers. Cotinine is subsequently metabolized to trans-3'-hydroxycotinine by CYP2A6. Nicotine and cotinine are glucuronidated to N-glucuronides mainly by UGT1A4 and partly by UGT1A9. Trans-3'- hydroxycotinine is glucuronidated to O-glucuronide mainly by UGT2B7 and partly by UGT1A9. Approximately 90% of the total nicotine uptake is eliminated as these metabolites and nicotine itself. The nicotine metabolism is an important determinant of the clearance of nicotine. Recently, advances in the understanding of the interindividual variability in nicotine metabolism have been made. There are substantial data suggesting that the large interindividual differences in cotinine formation are associated with genetic polymorphisms of the CYP2A6 gene. Interethnic differences have also been observed in the cotinine formation and the allele frequencies of the CYP2A6 alleles. Since the genetic polymorphisms of the CYP2A6 gene have a major impact on nicotine clearance, its relationships with smoking behavior or the risk of lung cancer have been suggested. The metabolic pathways of the glucuronidation of nicotine, cotinine, and trans-3'-hydroxycotinine in humans would be one of the causal factors for the interindividual differences in nicotine metabolism. This review mainly summarizes recent results from our studies.

References (57)

  • B.T. Ethell et al.

    The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases

    Biochem. Pharmacol.

    (2003)
  • W.C. Vial

    Cigarette smoking and lung disease

    Am. J. Med. Sci.

    (1986)
  • N.L. Benowitz

    Drug therapy

    Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Engl. J. Med.

    (1988)
  • E.W. Lee et al.

    Cigarette smoking, nicotine addiction, and its pharmacologic treatment

    Arch. Intern. Med.

    (1993)
  • M.A.H. Russell et al.

    Cigarette smoking: A dependence on high-nicotine boli

    Drug Metab. Rev.

    (1978)
  • M. Nakajima et al.

    Role of human cytochrome P4502A6 in C-oxidation of nicotine

    Drug Metab. Dispos.

    (1996)
  • M. Nakajima et al.

    Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes

    J. Pharmacol. Exp. Ther.

    (1996)
  • N.L. Benowitz et al.

    Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine

    J. Pharmacol. Exp. Ther.

    (1994)
  • G.D. Byrd et al.

    Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans- 3'-hydroxycotinine in smokers

    Drug Metab. Dispos.

    (1992)
  • J.R. Cashman et al.

    Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N' -oxide

    Chem. Res. Toxicol.

    (1992)
  • S.E. Murphy et al.

    Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism

    Chem. Res. Toxicol.

    (1999)
  • N.L. Benowitz et al.

    Deficient C-oxidation of nicotine

    Clin. Pharmacol. Ther.

    (1995)
  • Y. Rao et al.

    Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking

    Mol. Pharmacol.

    (2000)
  • G. Scherer et al.

    Pharmacokinetics of nicotine, cotinine, and 3?-hydroxycotinine in cigarette smokers

    Klin. Wochenschr.

    (1988)
  • M. Nakajima et al.

    Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans

    Clin. Pharmacol. Ther

    (2000)
  • M. Nakajima et al.

    Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans

    Clin. Pharmacol. Ther.

    (2001)
  • J.-T. Kwon et al.

    Nicotine metabolism and CYP2A6 allele frequencies in Koreans

    Pharmacogenetics

    (2001)
  • K. Nunoya et al.

    A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans

    J. Pharmacol. Exp. Ther.

    (1999)
  • Cited by (0)

    View full text